
You are here
Consultations
We conduct public consultations as part of our broader stakeholder engagement work, including on changes to regulatory requirements or practices, reviews of business processes, standards or guidelines, and TGA fees and charges.
Filters
Status
Categories
- Advertising (2) Apply Advertising filter
- Australian Register of Therapeutic Goods (ARTG) (1) Apply Australian Register of Therapeutic Goods (ARTG) filter
- Biologicals (2) Apply Biologicals filter
- Remove Blood and blood components filter Blood and blood components (0)
- Complementary medicines (7) Apply Complementary medicines filter
- Fees/Payments (1) Apply Fees/Payments filter
- Import/Export (1) Apply Import/Export filter
- Labelling/Packaging (1) Apply Labelling/Packaging filter
- Legislation (3) Apply Legislation filter
- Listed medicines (2) Apply Listed medicines filter
- Manufacturing (1) Apply Manufacturing filter
- Medical devices/IVDs (55) Apply Medical devices/IVDs filter
- Medical devices safety (1) Apply Medical devices safety filter
- Remove Medicinal cannabis filter Medicinal cannabis (1)
- Medicines (2) Apply Medicines filter
- Medicines safety (1) Apply Medicines safety filter
- Remove OTC medicines filter OTC medicines (12)
- Remove Other therapeutic goods filter Other therapeutic goods (1)
- Prescription medicines (6) Apply Prescription medicines filter
- Scheduling (55) Apply Scheduling filter
- Therapeutic Goods Administration (TGA) (2) Apply Therapeutic Goods Administration (TGA) filter
- Remove Therapeutic goods regulation filter Therapeutic goods regulation (2)
- (-) Remove Medicinal cannabis filter Medicinal cannabis
- (-) Remove Blood and blood components filter Blood and blood components
- (-) Remove OTC medicines filter OTC medicines
- (-) Remove Other therapeutic goods filter Other therapeutic goods
- (-) Remove Therapeutic goods regulation filter Therapeutic goods regulation
Potential reforms to medicinal cannabis manufacturing, labelling and packaging requirement
Closed on 29 January 2021
Proposed clarification that goods are therapeutic goods - goods containing folate substances in certain circumstances
Closed on 18 September 2019
Options for the future regulation of 'low risk' products
Closed on 12 May 2017
Loratadine and desloratadine: proposed advisory statements for medicines
Closed on 7 December 2012
Fexofenadine and loperamide: proposed advisory statements for medicines
Closed on 4 June 2012
Regulation of new excipients in topical non-prescription medicines
Closed on 16 December 2005